Actively Recruiting
Advanced Imaging for Pulmonary Fibrosis
Led by Peter Caravan · Updated on 2026-04-22
60
Participants Needed
1
Research Sites
205 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.
CONDITIONS
Official Title
Advanced Imaging for Pulmonary Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 80 years with diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD
- On stable dose immunosuppression treatment (prednisone, mycophenolate mofetil, mycophenolate sodium, and/or rituximab) for at least 3 months
- Pulmonary fibrosis defined by honeycombing, traction bronchiectasis, or reticular opacities on high-resolution CT performed within 1 year or at Visit 1
- Forced vital capacity (FVC) of 45% or more and diffusing capacity of lung for carbon monoxide (DLCO) of 25% or more predicted on pulmonary function tests at Visit 1
You will not qualify if you...
- Current or prior use of FDA approved anti-fibrotic therapy
- Extent of emphysema greater than extent of fibrosis
- Pregnancy or plans to become pregnant at baseline or during follow-up
- Contraindications to MRI
- Contraindications to gadolinium-based contrast agents
- Research-related radiation exposure exceeding 50 mSv in the prior year
- Estimated glomerular filtration rate (eGFR) less than 30 mL/min for individuals with chronic kidney disease
- Clinically significant pulmonary hypertension defined by use of pulmonary vasodilatory therapy
- Respiratory infection within the prior 6 weeks
- Smoking of any kind within the prior 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
S
Sydney Montesi, MD
CONTACT
C
Caroline Fromson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here